BioCryst Pharmaceuticals: Q3 Earnings Insights

BioCryst Pharmaceuticals BCRX reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.

BioCryst Pharmaceuticals beat estimated earnings by 17.86%, reporting an EPS of $-0.23 versus an estimate of $-0.28.

Revenue was up $34.83 million from the same period last year.

Last quarter the company beat on EPS by $0.02 which was followed by a 2.26% increase in the share price the next day.

Here's a look at BioCryst Pharmaceuticals's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	-0.34	-0.37	-0.3	-0.29
EPS Actual	-0.32	-0.40	-0.4	-0.33
Revenue Estimate	64.31M	51.36M	50.56M	39.38M
Revenue Actual	65.53M	49.92M	47.16M	40.99M

To track all earnings releases for BioCryst Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar